human papillomavirus vaccine, quadrivalent (Discontinued)

Brand and Other Names:Gardasil, hpv vaccine, quadrivalent
  • Print

Dosing & Uses

AdultPediatric

Prevention of Diseases Caused by HPV Types 6, 11, 16, & 18

October 31, 2016: No longer available in United States

0.5 mL IM x3 doses administered at 0, 1-2, & 6 months

For more vaccine information see http://www.cdc.gov/vaccines/schedules/hcp/index.html

Indicated for prevention in girls & women (9-26 years)

  • Cervical, vulvar, and vaginal cancer caused by HPV types 16 & 18
  • Genital warts (condyloma acuminata) caused by HPV types 6 & 11
  • CDC recommends 3-dose series for routine vaccination for girls at age 11-12 yr
  • Catch-up vaccination: 3-dose series for those aged 13 through 26 yr
  • If age 26 yr reached before vaccination series completed, remaining doses can be administered after age 26 yr (CDC guidelines)

Precancerous or dysplastic lesions in girls & women (9-26 years) caused by HPV types 6, 11, 16, & 18

  • Cervical intraepithelial neoplasia grade 2/3
  • Cervical adenocarcinoma in situ
  • Cervical intraepithelial neoplasia (CIN) grade 1
  • Vulvar intraepithelial neoplasia (VIN) grade 2/3
  • Vaginal intraepithelial neoplasia (VaIN) grade 2/3

Indicated for prevention in boys & men (9-26 years)

  • Genital warts (condyloma acuminata) caused by HPV types 6 & 11
  • CDC ACIP guidelines recommends routine immunization for all boys aged 11-12 years (MMWR Dec 23, 2011/Vol 60[50];1705-8)
  • Catch-up vaccination: 3-dose series for those aged 13 through 21 yr
  • Also, recommended for previously unvaccinated males aged 22–26 years who are immunocompromised, test positive for HIV infection, or who have sex with men

Anal cancer

  • Indicated for prevention of anal cancer and associated precancerous lesions caused by HPV types 6, 11, 16, and 18 people aged 9-26 years

Administration

Administer in deltoid region of upper arm or higher anterolateral area of thigh

Prevention of Diseases Caused by HPV Types 6, 11, 16, & 18

October 31, 2016: No longer available in United States

0.5 mL IM x 3 doses at 1, 1-2, and 6 months

For more vaccine information see http://www.cdc.gov/vaccines/schedules/hcp/index.html

CDC recommendations

  • CDC recommends routine vaccination for females at age 11 or 12 yr with either HPV2 or HPV4; may begin vaccination series as early as age 9 yr

Indicated for prevention in girls & women (9-26 years)

  • Cervical, vulvar, and vaginal cancer caused by HPV types 16 & 18
  • Genital warts (condyloma acuminata) caused by HPV types 6 & 11
  • Catch-up vaccination: 3-dose series for those aged 13 through 26 yr
  • If age 26 yr reached before vaccination series completed, remaining doses can be administered after age 26 yr (CDC guidelines)

Precancerous or dysplastic lesions in girls & women (9-26 years) caused by HPV types 6, 11, 16, & 18

  • Cervical intraepithelial neoplasia grade 2/3
  • Cervical adenocarcinoma in situ
  • Cervical intraepithelial neoplasia (CIN) grade 1
  • Vulvar intraepithelial neoplasia (VIN) grade 2/3
  • Vaginal intraepithelial neoplasia (VaIN) grade 2/3

Indicated for prevention in boys & men (9-21 years)

  • Genital warts (condyloma acuminata) caused by HPV types 6 & 11
  • Catch-up vaccination: 3-dose series for those aged 13 through 21 yr

Anal cancer

  • Indicated for prevention of anal cancer and associated precancerous lesions caused by HPV types 6, 11, 16, and 18 people aged 9-26 years
Next:

Interactions

Interaction Checker

and human papillomavirus vaccine, quadrivalent

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            >10%

            Inj site pain

            Inj site erythema & swelling

            Fever

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Age <9 yr or >26 yr

            Bleeding disorder, anticoagulant therapty (unless benefits outweigh risks)

            Cautions

            Individuals who develop symptoms indicative of hypersensitivity after 1st dose should not receive additional doses

            Monitor for 15 min following vaccination for syncope/convulsive syncope

            Not shown to be protective against non-vaccine HPV types

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B; Not recommended for use in pregnant women

            Women who become pregnant after initiating the vaccination series, no intervention is needed; delay the remaining doses until completion of pregnancy

            Lactation: not known whether excreted in breast milk, use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Recombinant vaccine prepared from L1 protein of HPV types 6, 11, 16 & 18

            Duration: unknown

            These products convey active immunity via stimulation of production of endogenously produced antibodies

            The onset of protection from disease is relatively slow, but duration is long lasting (years)

            Previous
            Next:

            Images

            Previous
            Next:
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.